Ken Griffin Oncolytics Biotech Inc Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Oncolytics Biotech Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 137,085 shares of ONCY stock, worth $159,018. This represents 0.0% of its overall portfolio holdings.

Number of Shares

137,085

Previous 162,765 15.78%

Holding current value

$159,018

Previous $172,000 21.51%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.99 - $1.24 $25,423 - $31,843	-25,680 Reduced 15.78%	137,085 $135,000
Q1 2024 May 15, 2024	BUY	$0.89 - $1.36 $43,503 - $66,476	48,880 Added 42.92%	162,765 $172,000
Q4 2023 Feb 14, 2024	BUY	$1.22 - $2.09 $138,939 - $238,019	113,885 New	113,885 $153,000
Q1 2023 May 15, 2023	BUY	$1.2 - $1.91 $60,704 - $96,621	50,587 Added 135.73%	87,858 $105,000
Q4 2022 Feb 14, 2023	BUY	$1.17 - $2.12 $43,607 - $79,014	37,271 New	37,271 $60,000
Q2 2022 Aug 15, 2022	SELL	$0.85 - $1.59 $9,893 - $18,506	-11,639 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.31 - $2.02 $109,641 - $169,065	-83,696 Reduced 87.79%	11,639 $18,000
Q4 2021 Feb 14, 2022	BUY	$1.39 - $2.3 $108,902 - $180,198	78,347 Added 461.19%	95,335 $132,000
Q3 2021 Nov 15, 2021	SELL	$1.93 - $2.77 $23,933 - $34,350	-12,401 Reduced 42.2%	16,988 $36,000
Q2 2021 Aug 16, 2021	SELL	$2.6 - $4.64 $51,971 - $92,748	-19,989 Reduced 40.48%	29,389 $81,000
Q1 2021 May 17, 2021	BUY	$2.32 - $4.11 $114,556 - $202,943	49,378 New	49,378 $188,000
Q4 2020 Feb 16, 2021	SELL	$1.71 - $4.03 $39,567 - $93,250	-23,139 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$1.58 - $2.15 $23,537 - $32,028	-14,897 Reduced 39.17%	23,139 $39,000
Q2 2020 Aug 14, 2020	BUY	$1.33 - $2.76 $50,587 - $104,979	38,036 New	38,036 $72,000
Q1 2020 May 15, 2020	SELL	$0.98 - $4.28 $31,815 - $138,950	-32,465 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$0.42 - $4.76 $6,530 - $74,013	15,549 Added 91.92%	32,465 $154,000
Q3 2019 Nov 14, 2019	BUY	$0.54 - $1.71 $9,134 - $28,926	16,916 New	16,916 $9,000
Q2 2019 Aug 14, 2019	SELL	$1.63 - $1.95 $48,117 - $57,564	-29,520 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$1.77 - $2.31 $52,250 - $68,191	29,520 New	29,520 $0

Others Institutions Holding ONCY

# of Institutions

Shares Held

1.32M

Call Options Held

Put Options Held

View Full List

About ONCOLYTICS BIOTECH INC

Ticker ONCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,867,400
Market Cap $67.1M
Description
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a...

More about ONCY

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account